Aurobindo receives FDA approval for enalapril maleate oral solution
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S.
Pharmacy
Rite Aid sells Elixir Solutions Business to MedImpact
Rite Aid Corp. announced that the U.S. Bankruptcy Court for the District of New Jersey has approved the sale of the company’s Elixir Solutions Business to MedImpact Healthcare Systems, Inc. (MedImpact), an independent pharmacy benefit solutions company.
WBA has reached $360M settlement in drug-pricing dispute with Humana
According to published reports, Walgreens Boots Alliance (WBA) has agreed to pay Humana $360M in settlement for a lawsuit that alleged that the retail-pharmacy chain overcharged for prescription-drug reimbursements.
Health care outlook 2024: Steve Anderson, president, CEO, NACDS
a great friend of NACDS — stand the
Health care outlook 2024: John O’Brien, president and CEO, NPC
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. 2023 was a pivotal year for health policy, to say the least.
Health care outlook 2024: Scott Melville, president and CEO, CHPA
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year.
Health care outlook 2024: Micah Cost, CEO, PQA
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. Former Defense Secretary Donald Rumsfeld once observed that “there are known knowns. There are things we know we know. We also know there are known unknowns.
Health care outlook 2024: Ronald Piervincenzi, CEO, U.S. Pharmacopeia
In the second of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The past year was significant for the pharmaceutical industry, as we witnessed major milestones and celebrated advancements in innovation.
NACDS unveils new spot on PBM reform
ARLINGTON, Va. – A new television ad from NACDS urges Congress to enact bipartisan pharmacy benefit manager (PBM) reforms that it has advanced in this legislative session.
Health care outlook 2024: Sheila Arquette, president and CEO, NASP
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. Specialty pharmacy continues to be dynamic, demanding and disruptive.
Health care outlook 2024: Sandra Hanna, CEO, Neighbourhood Pharmacies
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. 2023 was a momentous year for community pharmacy in Canada.
Health care outlook 2024: B. Douglas Hoey CEO, NCPA
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review. The date January 1 can have varying meanings for people.
Health care outlook 2024: Lee Ann Stember, president and CEO, NCPDP
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year.
Health care outlook 2024: Peter Matz, director of Food, Pharmacy and Health Policy at FMI – The Food Industry Association
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review.
Health care outlook 2024: Michael Hogue, CEO, APhA
In the first of a two-part series, leaders of industry associations present their expectations for pharmacy operators for this year. The views of other organizations will appear in the next issue of Chain Drug Review.